Clinical Trial Update: Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) [Phase 1, Phase 2]

View source ↗

Summary

This update summarizes a Phase 1/2 study evaluating the pharmacokinetics and safety of epratuzumab in Japanese patients with systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Epratuzumab (epratuzumab)

Snippet

Sponsor: UCB Pharma | Conditions: Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED